Skip to main content
. 2022 Apr 2;16(9):1380–1396. doi: 10.1093/ecco-jcc/jjac045

Table 5.

Outcomes by monogenic versus non-monogenic disease.

Monogenic [n = 17] Non-monogenic [n = 199] OR [95% CI] p-value
H=Hospitalisation 15 [88.2%] 139 [69.8%] 3.24 [0.88, 20.95] 0.12
ICU hospitalisation 9 [52.9%] 13 [6.5%] 14.54 [4.56, 49.98] <0.001
G-tubea 7 [41.2%] 11 [5.5%] 11.96 [3.74, 37.82] <0.001
TPN in hospital 8 [47.1%] 23 [11.6%] 6.80 [2.35, 19.58] <0.001
TPN at home 2 [11.8%] 2 [1.0%] 13.13 [1.49, 115.98] 0.01
Surgery 4 [23.5%] 37 [18.6%] 1.35 [0.36, 4.06] 0.62
5-ASA exposure 8 [47.1%] 164 [82.4%] 0.19 [0.07, 0.53] 0.001
5-ASA failure 5 [62.5%] 111 [67.7%] 0.92 [0.19, 6.62] 0.93
Anti-TNF exposure 5 [29.4%] 111 [55.8%] 0.33 [0.10, 0.93] 0.04
Anti-TNF failure 3 [60.0%] 56 [50.5%] 2.57 [0.32, 52.92] 0.42
Weight z-score <-2 at 3-year follow-up 2/9 [22.2%] 9/146 [6.2%] 3.00 [0.43,13.13] 0.19
Height z-score <-2 at 3-year follow-up 4/9 [44.4%] 12/146[8.2%] 5.17 [1.30, 17.60] 0.01
BMI z-score <-2 at 3-year follow-up 0/9 [0.0%] 3/146 [2.1%] n.e. 1.00
HSCT 7 [41.2%] 0 [0.0%] n.e. <0.001
Death 2 [11.8%] 0 [0.0%] n.e. 0.006

n.e. = not estimable.

Includes one patient with monogenic disease who had gastrojejunal [GJ] tube.